Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer

Title
Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer
Authors
Keywords
Triple-negative breast cancer, Foretinib, MET targeting, Clinical activity
Journal
BREAST CANCER RESEARCH AND TREATMENT
Volume 157, Issue 1, Pages 109-116
Publisher
Springer Nature
Online
2016-04-26
DOI
10.1007/s10549-016-3812-1

Ask authors/readers for more resources

Reprint

Contact the author

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started